About Entasis Therapeutics
Entasis Therapeutics is a Healthcare company based in Waltham (United States) founded in 2015, and was acquired by Innoviva in May 2022. Small molecules for drug-resistant bacterial infections are developed. Entasis Therapeutics has raised $121.9 million across 5 funding rounds from investors including Astrazeneca, Blackstone and TPG. The company has 40 employees. The company was acqui-hired. Entasis Therapeutics offers products and services including GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is Innoviva Specialty Therapeutics. Its competitors include Paratek Pharma, Spero Therapeutics and Cempra; 3 of its 3 listed competitors have raised funding.
Company details
Entasis Therapeutics was founded in 2015 and is based in Waltham, United States, within the biotechnology sector. Focus is placed on developing small-molecule antibiotics targeting multidrug-resistant Gram-negative infections, such as those caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae. A single-dose oral therapy for both susceptible and resistant Neisseria gonorrhoeae is also pursued. The lead candidate, ETX0914, is advanced as an oral antibiotic for uncomplicated gonorrhea treatment.
- Headquarters Waltham, United States
- Employees 40
- Stage Public
- SectorsHealthcare
- Website entasistx.com
- Social LinkedIn X
- Acquired by Innoviva (May 2022)
- Legal Name Innoviva Specialty Therapeutics
- Annual Revenue$7 M (USD)40as on Dec 31, 2019
- Total Equity Funding$121.9M (USD)
in 5 rounds
- Latest Funding Round$25M (USD), Post-IPO
Aug 2020
- InvestorsAstrazeneca
& 8 more
- Employee Count40
- Acquired byInnoviva
(May 2022)
Products & Services of Entasis Therapeutics
Entasis Therapeutics offers a comprehensive portfolio of products and services, including GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN.
Treats critical care conditions like low blood pressure.
Fights serious bacterial infections in hospitalized patients.
Addresses infections caused by drug-resistant microorganisms.
Targets uncomplicated gonorrhea infections in clinical development.
Funding Insights of Entasis Therapeutics
Entasis Therapeutics has successfully raised a total of $121.9M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $121.9M
- Total Rounds 5
- Last Round Post-IPO — $25M
- First Round $40M
(Mar 2015)
- Investors Count 9
All 5 funding rounds of Entasis Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $25M | Post-IPO | – | – | |
| Apr 2020 | $35M | Post-IPO | – | – | |
| Sep 2017 | $31.9M | Series B | – | – | |
| Apr 2016 | $50M | Series B | – | – | |
| Mar 2015 | $40M | Series A | – | – |
9 investors in total: 9 institutional.
Investors in Entasis Therapeutics
Entasis Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Blackstone and TPG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Respiratory prescription drugs are developed and in-licensed for COPD treatment. | 1996 | inva.com | Brisbane, United States | |
A global healthcare investment firm supporting therapeutic-focused companies. | 2017 | pivotalbiovp.com | San Francisco, United States | |
Eventide Mutual Funds is managed by Eventide Asset Management, offering investment solutions. | eventidefunds.com | Boston, United States | ||
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom |
Investor details for Entasis Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Entasis Therapeutics
8 people are tracked at Entasis Therapeutics (7 in board & advisors, 1 in team); the tracked headcount is 40.
| Name | Role | Group |
|---|---|---|
Paul G Ambrose | Clinical Board Member | Board & advisors |
Mark Noe | Clinical Board Member | Board & advisors |
Karen Bush | Clinical Board Member | Board & advisors |
Louis B. Rice | Clinical Board Member | Board & advisors |
Andrew F. Shorr | Clinical Board Member | Board & advisors |
Helen W. Boucher | Clinical Board Member | Board & advisors |
Kerry Laplante | Clinical Board Member | Board & advisors |
Betzy Keiley | General Counsel | Team |
Complete people profiles for Entasis Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Entasis Therapeutics
5 dated milestones of Entasis Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Entasis Therapeutics is founded.
- Funding First funding round of $40.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $25.0M.
- Exit Acquired by Innoviva.
Competitors of Entasis Therapeutics
Entasis Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Paratek Pharma, Spero Therapeutics and Cempra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| cempra.com | 2006 | Chapel Hill, United States | $149.5M | 78 | Clinical-stage pharmaceutical company focused on developing antibacterials |
Detailed competitors of Entasis Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Entasis Therapeutics (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Entasis Therapeutics
Complete news archive for Entasis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Entasis Therapeutics
Entasis Therapeutics was founded in 2015.
Entasis Therapeutics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Entasis Therapeutics is a funded company, having raised a total of $121.9M across 5 funding rounds to date. The company's 1st funding round was a Series A of $40M, raised on Mar 2015.
Entasis Therapeutics has 40 employees.
Annual revenue of Entasis Therapeutics is $7M as on Dec 31, 2019.
Entasis Therapeutics was founded in 2015 and is based in Waltham, United States, within the biotechnology sector. Focus is placed on developing small-molecule antibiotics targeting multidrug-resistant Gram-negative infections, such as those caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae. A single-dose oral therapy for both susceptible and resistant Neisseria gonorrhoeae is also pursued. The lead candidate, ETX0914, is advanced as an oral antibiotic for uncomplicated gonorrhea treatment.
Entasis Therapeutics's top competitors include Spero Therapeutics, Paratek Pharma and Cempra.
Entasis Therapeutics offers GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN.
Entasis Therapeutics has 9 investors. Key investors include Astrazeneca, Blackstone, TPG, Innoviva, and Frazier Healthcare Partners.
Entasis Therapeutics operates through Innoviva Specialty Therapeutics.
Yes. Entasis Therapeutics was acquired by Innoviva in May 2022.